Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Age ≥ 18 years~* Histologically confirmed GBM in first or second relapse~* Radiographic demonstration of disease progression following prior therapy~* Bi-dimensionally measurable disease with a minimum measurement of 1 cm (10 mm) in one diameter on MRI performed within 14 days prior to first treatment (Day 0)~* An interval of ≥ 4 weeks since prior surgical resection~* Prior standard radiation for GBM~* Prior chemotherapy: first-relapse subjects~* Prior chemotherapy: second-relapse subjects~* Recovery from the effects of prior therapy, including the following: 4 weeks from cytotoxic agents (except 6 weeks from nitrosoureas, 3 weeks from procarbazine, 2 weeks from vincristine); 4 weeks from any investigational agent; 1 week from non-cytotoxic agents; 8 weeks from radiotherapy to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field~* Prior therapy with gamma knife or other focal high-dose radiation is allowed but the subject must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field~* Karnofsky performance status ≥ 70~* Life expectancy \> 12 weeks~* Use of an effective means of contraception in males and in females of childbearing potential~* Ability to comply with study and follow-up procedures~Exclusion Criteria:~* Prior treatment with irinotecan, bevacizumab, or another VEGF or VEGFR-targeted agent~* Prior treatment with prolifeprospan 20 with carmustine wafer~* Prior intracerebral agents~* Need for urgent palliative intervention for primary disease (e.g., impending herniation)~* Evidence of recent hemorrhage on baseline MRI of the brain with the following exceptions: Presence of hemosiderin; Resolving hemorrhagic changes related to surgery; Presence of punctate hemorrhage in the tumor~* Received more than two treatment regimens for Grade III and/or Grade IV glioma~* Blood pressure of \> 150 mmHg systolic and \> 100 mmHg diastolic~* History of hypertensive encephalopathy~* New York Heart Association (NYHA) Grade II or greater CHF~* History of myocardial infarction or unstable angina within 6 months prior to Day 0~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 0~* Evidence of bleeding diathesis or coagulopathy~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* History of intracerebral abscess within 6 months prior to Day 0~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study~* Minor surgical procedures (excluding placement of a vascular access device), stereotactic biopsy, fine needle aspirations, or core biopsies within 7 days prior to Day 0~* Serious non-healing wound, ulcer, or bone fracture~* Pregnancy (positive pregnancy test) or lactation~* Known hypersensitivity to any component of bevacizumab~* History of any other malignancy within 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)~* Pregnant or nursing females~* Unstable systemic disease, including active infection, uncontrolled hypertension, or serious cardiac arrhythmia requiring medication~* Subjects unable to undergo an MRI with contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete